Ingalls & Snyder LLC’s Bristol-Myers Squibb BMY Stock Holding History

Ingalls & Snyder LLC’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,200	Closed	-$415K	–	471
2025 Q3	$415K	Hold	9,200	–	–	0.01%	321
2025 Q2	$426K	Sell	9,200 -1,500	-14%	-$73.6K	0.02%	308
2025 Q1	$653K	Sell	10,700 -2,000	-16%	-$117K	0.02%	263
2024 Q4	$718K	Hold	12,700	–	–	0.03%	249
2024 Q3	$657K	Hold	12,700	–	–	0.03%	270
2024 Q2	$527K	Hold	12,700	–	–	0.02%	283
2024 Q1	$689K	Buy	+12,700	New	+$647K	0.03%	257
2022 Q3	–	Sell	-14,600	Closed	-$1.12M	–	437
2022 Q2	$1.12M	Sell	14,600 -3,700	-20%	-$282K	0.06%	185
2022 Q1	$1.34M	Hold	18,300	–	–	0.06%	187
2021 Q4	$1.14M	Hold	18,300	–	–	0.05%	211
2021 Q3	$1.08M	Hold	18,300	–	–	0.05%	221
2021 Q2	$1.22M	Buy	+18,300	New	+$1.19M	0.05%	221

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ingalls & Snyder LLC's BMY Position: Q2 2026 in Review

Ingalls & Snyder LLC reduced its Bristol-Myers Squibb (BMY) stake by 5.2% in Q2 2026, selling an estimated $234K and leaving 74,298 shares worth $4.28M. The position accounts for 0.12% of the portfolio, ranked #119.

Ingalls & Snyder LLC first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $36.4M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Ingalls & Snyder LLC held 74,298 shares of Bristol-Myers Squibb worth $4.28M as of Q2 2026.
Ingalls & Snyder LLC sold 4,072 Bristol-Myers Squibb shares in Q2 2026, an estimated $234K.
Bristol-Myers Squibb made up 0.12% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #119 holding.
Ingalls & Snyder LLC first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
Ingalls & Snyder LLC's Bristol-Myers Squibb position peaked at $36.4M in Q2 2022.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.